The global oncology market last year set several records, though the industry continues to struggle with long development timelines, which in 2018 averaged 10.5 years from patent filing to regulatory approval and launch, according to a recent Iqvia report.
Biomarkers have the potential to improve drug development productivity by 34% over the next five years, during which period pre-screened patient pools and the application of predictive analytics also will help address the increasing complexity of clinical...
Iqvia acquired UK-based Linguamatics in January 2019 as part of the company's commitment to deliver value from artificial intelligence and machine learning.
Driven by a more than 20% increase in adverse event volumes, Iqvia has developed a SaaS safety platform designed to reduce the cost and complexity of pharmacovigilance activities – and help companies add value back into their business, says VP.
The FDA recently released open source code and technical documents for its new mobile app – MyStudies – which is designed to collect information about medication use, health system touchpoints, and patient-reported outcomes.
Iqvia reported a record quarter of contracted bookings during its third quarter earnings call, as the company continues to invest in its technology platform while securing new customers, say CEO.
Iqvia says its collaboration with Genomics England will help drugmakers and academics draw insights from clinical-genomic datasets – the ‘future of real-world research.’
Iqvia is expanding its alliance with Salesforce through which the companies will release SaaS and technology-enabled services to automate clinical trial processes and reduce patient burden.
Iqvia recently announced its second quarter 2018 results, which came in “above the high end” of the company’s expectations at $2.567bn, said CEO Ari Bousbib.
Iqvia has launched a new suite of virtual study options to challenge the traditional clinical research mindset with a patient-centric approach, says company executive.
